Abilify Discmelt

Name: Abilify Discmelt

Abilify Discmelt Drug Class

Abilify Discmelt is part of the drug class:

  • Other antipsychotics

Abilify Discmelt Overdose

If you take too much Abilify Discmelt call your healthcare provider or local Poison Control Center, or seek emergency medical attention right away.

If Abilify Discmelt is administered by a healthcare provider in a medical setting, it is unlikely that an overdose will occur. However, if overdose is suspected, seek emergency medical attention.

Usual Adult Dose for Depression

As adjunctive treatment for patients already taking an antidepressant:
Initial dose: 2 to 5 mg orally once a day
Target dose: 5 to 10 mg orally once a day; titrate in increments up to 5 mg per day at intervals of no less than 1 week
Maximum dose: 15 mg per day

Comments: -Patients should be periodically reassessed to determine need for continued treatment.
-The oral solution and oral tablets can be substituted on a mg-per-mg basis up to the 25 mg dose level.

Use: As an adjunct to antidepressant therapy for the treatment of major depressive disorder.

Usual Pediatric Dose for Bipolar Disorder

Age: 10 years or older: As monotherapy or as adjunctive therapy with lithium or valproate:
Initial Dose: 2 mg orally once a day
After 2 days: Titrate to 5 mg orally once a day
After 4 days: Titrate to 10 mg orally once a day
Target Dose: 10 mg orally once a day; dose increases, if needed should be in 5 mg increments at 2-week intervals in order to allow time to achieve steady state
Maximum Dose: 30 mg per day

Comments: The dose for maintenance treatment is the same dose needed to stabilize patients during acute treatment; periodically reassess need for maintenance treatment.
-The oral solution and oral tablets can be substituted on a mg-per-mg basis up to the 25 mg dose level; patients receiving 30 mg tablets should receive 25 mg of the oral solution.
-Dosage adjustments are recommended in patients who are known CYP450 2D6 poor metabolizers and taking concomitant CYP450 inhibitors or inducers; see dosage adjustment section for specific adjustments.

Uses: This drug may be used as monotherapy or as an adjunct to lithium or valproate for the acute treatment of manic and mixed episodes associated with bipolar I disorder and for maintenance treatment of bipolar I disorder.


Data not available

Other Comments

Administration advice:
Oral Formulations:
Take orally with or without food; swallow tablet whole
-Oral solution 1 mg/mL: Use calibrated dosing cup
-Oral disintegrating tablet (ODT): Remove tablet from blister by peeling back the foil just prior to administration; do not push tablet through foil as this could damage tablet. With dry hands, place tablet on tongue and allow to disintegrate; liquid is not required, but may be taken if needed.
-Missed doses: Take the missed dose as soon as remembered. If it is almost time for the next dose, skip the missed dose and take the next dose at the regular time; do not take 2 doses at the same time.

Immediate-Release IM formulation (9.75 mg/1.3 mL):
- Inject IM slowly, deep into muscle mass; do not give IV or subcutaneously

Extended-Release IM Injectable Suspensions: To be administered by a health care professional using the appropriate enclosed safety needles
Aripiprazole Extended-Release Injectable Suspension [Abilify Maintena(R)]:
-Administer by deep IM gluteal injection once a month; do not administer IV or subcutaneously
Aripiprazole lauroxil Extended-Release Injectable Suspension [Aristada(TM)]:
-Administer by deep IM gluteal (441 mg, 662 mg, or 882 mg) or deltoid (441 mg only) injection once a month or every 6 weeks as prescribed; do not administer IV or subcutaneously

Storage requirements:
-Oral solution: Opened bottles can be used for up to 6 months after opening; do not use beyond the expiration date on the bottle
-Immediate-release injection (9.75 mg/1.3 mL vials): Protect from light by storing in original packaging until ready for use.
-Extended-Release [Abilify Maintena(R)] pre-filled dual chamber syringes: Store below 30C (86F); do not freeze; protect form light by storing in original packaging until ready to use.
-Extended-Release [Abilify Maintena(R)] vials: Store at 25C (77F); do not freeze
-Extended-Release [Aristada(TM)] pre-filled syringes: Store at room temperature 20C to 25C (68F to 77F) with excursions permitted between 15C and 30C (59F and 86F)

Reconstitution/preparation techniques: The manufacturer product information should be consulted.

-Patients should be periodically reassessed to determine continued need for treatment.

-Hematologic: CBC frequently during the first few months in patients with preexisting low WBC and/or a prior history of drug-induced leukopenia or neutropenia.
-Metabolic: Monitor for increases in blood sugar, weight, and lipids
-Psychiatric: Monitor for clinical worsening and suicidality; close supervision of high-risk patients should accompany drug therapy.
-Monitor for pathological gambling and decreased impulse control, especially in those with a history of these behaviors.

Patient advice:
-Patients, families, and caregivers should report worsening of depression, suicidal ideation, or any unusual changes in behavior, especially during early antidepressant treatment and when doses are adjusted up or down. Decreased impulse control has been reported, and any patient experiencing signs/symptoms of poor impulse control should report the side effect.
-Patients should be advised to speak with health care providers if they plan to take any new medications including over the counter medications as there are potential drug interactions requiring dose adjustments.
-This drug may impair judgment, thinking, or motor skills; have patients avoid driving or operating machinery until adverse effects are determined.
-Advise patients to speak to physician or health care professional if they are pregnant, intend to become pregnant, or are breastfeeding.
-Advise patients that this drug may cause metabolic changes such as increases in blood sugar, body weight and lipids.
-Patients should avoid overheating and dehydration.

What is Abilify Discmelt?

Abilify Discmelt is an antipsychotic medication. It works by changing the actions of chemicals in the brain.

Abilify Discmelt is used to treat the symptoms of psychotic conditions such as schizophrenia and bipolar I disorder (manic depression). It is not known if this medicine is safe or effective in children younger than 13 with schizophrenia, or children younger than 10 with bipolar disorder.

Abilify Discmelt is also used together with other medicines to treat major depressive disorder in adults.

Abilify Discmelt is also used in children 6 years or older who have Tourette's disorder, or symptoms of autistic disorder (irritability, aggression, mood swings, temper tantrums, and self-injury).

Abilify Discmelt may also be used for purposes not listed in this medication guide.

What should I avoid while taking Abilify Discmelt?

This medication may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be alert. Avoid getting up too fast from a sitting or lying position, or you may feel dizzy. Dizziness or severe drowsiness can cause falls, fractures, or other injuries.

Avoid drinking alcohol. Dangerous side effects could occur.

Avoid becoming overheated or dehydrated. Drink plenty of fluids, especially in hot weather and during exercise. It is easier to become dangerously overheated and dehydrated while you are taking Abilify Discmelt.

What other drugs will affect Abilify Discmelt?

Taking Abilify Discmelt with other drugs that make you sleepy or slow your breathing can cause dangerous or life-threatening side effects. Ask your doctor before taking a sleeping pill, narcotic pain medicine, prescription cough medicine, a muscle relaxer, or medicine for anxiety, depression, or seizures.

Many other drugs can interact with Abilify Discmelt. This includes prescription and over-the-counter medicines, vitamins, and herbal products. Not all possible interactions are listed here. Tell your doctor about all your medications and any you start or stop using during treatment with this medicine.